Alaunos Therapeutics, Inc. (TCRT)
NASDAQ: TCRT · Real-Time Price · USD
1.860
+0.110 (6.29%)
At close: Nov 3, 2026, 4:00 PM EST
1.751
-0.109 (-5.84%)
After-hours: Nov 3, 2026, 7:30 PM EST
Company Description
Alaunos Therapeutics, Inc., a pre-clinical stage biopharmaceutical company that develops orally administered small-molecule therapeutics for the treatment of obesity and related metabolic disorders.
It develops non-hormonal, non-incretin approach, and unlike hormone-based treatments, such as GLP-1 drugs.
The company also develops hunTR TCR discovery platform to target driver mutations. Alaunos Therapeutics, Inc. was founded in 2003 and is based in Fort Lauderdale, Florida.
Alaunos Therapeutics, Inc.
| Country | United States |
| Founded | 1998 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 1 |
| CEO | Holger Weis |
Contact Details
Address: 501 E. Las Olas Blvd., Suite 300 Fort Lauderdale, Florida 33301 United States | |
| Phone | 346 355 4099 |
| Website | alaunos.com |
Stock Details
| Ticker Symbol | TCRT |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001107421 |
| CUSIP Number | 98973P309 |
| ISIN Number | US98973P3091 |
| Employer ID | 84-1475642 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Holger Weis CPA | Chairman of the Board and Chief Executive Officer |
| Ferdinand Groenewald | Vice President of Finance and Corporate Secretary |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Oct 23, 2026 | 8-K | Current Report |
| Oct 21, 2026 | 8-K | Current Report |
| Oct 15, 2026 | SCHEDULE 13D/A | Filing |
| Oct 15, 2026 | SCHEDULE 13D | Filing |
| Oct 13, 2026 | 8-K | Current Report |
| Oct 9, 2026 | 8-K | Current Report |
| Sep 22, 2026 | 8-K | Current Report |
| Sep 21, 2026 | 424B3 | Prospectus |
| Sep 17, 2026 | 8-K | Current Report |
| Aug 14, 2026 | 10-Q | Quarterly Report |